Skip to search boxSkip to navigationSkip to main content

Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

  • Ingrid Lorese Tablazon
    ,
  • Lauren E. Howard
    ,
  • Amanda M. De Hoedt
    ,
  • William J. Aronson
    ,
  • Christopher J. Kane
    ,
  • Christopher L. Amling
*Corresponding author for this work
  • Durham Veterans Affairs Medical Center
    ,
  • Duke University
    ,
  • VA Medical Center
    ,
  • University of California at Los Angeles
    ,
  • University of California at San Diego
    ,
  • Department of Veterans Affairs
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Background: Although skeletal-related events (SREs) are linked with a reduced quality of life and worse outcomes, to the authors' knowledge the factors that predict SREs are minimally understood. The objective of the current study was to identify predictors of SREs and all-cause mortality among men with metastatic castration-resistant prostate cancer (mCRPC). Methods: Data were collected on 837 men with bone mCRPC at 8 Veterans Affairs medical centers within the Shared Equal Access Regional Cancer Hospital (SEARCH) database from 2000 through 2017. Patients were followed to assess development of SREs (pathological fracture, radiotherapy to bone, spinal cord compression, or surgery to bone). Cox proportional hazards models were used to evaluate predictors of SREs and mortality. Results: Of the 837 men with bone mCRPC, 287 developed a SRE and 740 men died (median follow-up, 26 months). Bone pain was found to be the strongest predictor of SREs (hazard ratio [HR], 2.96; 95% CI, 2.25-3.89). A shorter time from CRPC to the development of metastasis (HR, 0.92; 95% CI, 0.85-0.99), shorter progression to CRPC (HR, 0.94; 95% CI, 0.91-0.98), and visceral metastasis at the time of diagnosis of bone metastasis (HR, 1.91; 95% CI, 1.18-3.09) were associated with an increased risk of SREs. Ten or more bone metastases (HR, 2.17; 95% CI, 1.72-2.74), undergoing radical prostatectomy (HR, 0.73; 95% CI, 0.61-0.89), shorter progression to CRPC (HR, 0.97; 95% CI, 0.94-0.99), older age (HR, 1.03; 95% CI, 1.02-1.04), higher prostate-specific antigen level at the time of diagnosis of metastasis (HR, 1.21; 95% CI, 1.14-1.28), bone pain (HR, 1.44; 95% CI, 1.23-1.70), and visceral metastasis (HR, 1.72; 95% CI, 1.23-2.39) were associated with an increased mortality risk. Conclusions: Among men with bone mCRPC, bone pain was found to be the strongest predictor of SREs and the number of bone metastases was a strong predictor of mortality. If validated, these factors potentially may be used for risk stratification and for SRE prevention strategies.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 4003-4010 (8 pages)

Journal (Volume, Issue Number)

Cancer (Volume 125, Issue 22)

Publication milestones

  • Published - 11/15/2019

Publication status

Published - 11/15/2019

ISSN

0008-543X

Publication IDs

  • Scopus: 85070665981
  • PubMed: 31390061

Publication metrics

Metrics

SciVal
FWCI
0.52
SciVal
Author count
10
SciVal
citations
4
SciVal
Paper percentile
72
Fractional count
1
Fractional count
0.10
Fractional count
9
Fractional count
0.90
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
22
Captures
42

Funding Details

Support for this study was provided by the National Institutes of Health/National Cancer Institute under award number R01CA231219 and National Institutes of Health grant K24 CA160653. This study was conducted with the support of Bayer Pharmaceuticals (to Stephen J. Freedland).
FundersFunding numbers
NIH
K24 CA160653
NCI
R01CA231219
Bayer Pharmaceuticals
-